Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $238.6 million.

  • Adma Biologics' Shares Outstanding (Weighted Average) rose 171.87% to $238.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.6 million, marking a year-over-year increase of 171.87%. This contributed to the annual value of $233.1 million for FY2024, which is 406.6% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Shares Outstanding (Weighted Average) is $238.6 million, which was up 171.87% from $241.5 million recorded in Q2 2025.
  • Adma Biologics' 5-year Shares Outstanding (Weighted Average) high stood at $241.5 million for Q2 2025, and its period low was $115.7 million during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Shares Outstanding (Weighted Average) value was $222.7 million (recorded in 2023), while the average stood at $202.3 million.
  • As far as peak fluctuations go, Adma Biologics' Shares Outstanding (Weighted Average) soared by 6934.87% in 2022, and later skyrocketed by 171.87% in 2025.
  • Over the past 5 years, Adma Biologics' Shares Outstanding (Weighted Average) (Quarter) stood at $139.6 million in 2021, then skyrocketed by 41.77% to $197.9 million in 2022, then increased by 13.19% to $224.0 million in 2023, then increased by 4.07% to $233.1 million in 2024, then grew by 2.37% to $238.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $238.6 million in Q3 2025, compared to $241.5 million in Q2 2025 and $237.8 million in Q1 2025.